Both men and women with MS can have thinking problems, but the brain areas linked to those problems differ by sex, with women showing stronger links to damaged white matter.
Researchers scanned 287 people with MS and compared them to healthy people to see how brain damage links to thinking skills. They found about the same share of thinking problems in men and women, but men did worse on remembering words while women had more trouble quickly finding words. Damage to white matter (the brain's wiring, like electrical cables) in important pathways was tied to worse thinking in both sexes, and this link was stronger in women. The 'normal-looking' white matter (which can hide subtle damage) also showed tiny changes that matched thinking problems, especially in women; think of it like cables that look okay but have frayed insulation. Gray matter loss (the brain's processing centers, like computer chips) was tied to thinking problems in both sexes but showed different patterns: men had more outer-cortex loss while women had more deep-brain loss.
People with MS should care because this study helps explain why thinking problems can feel different for men and women and points to different brain areas to watch. Caregivers and family can use this to better understand why a loved one may struggle with memory versus word finding, like when a grocery list is forgotten or a name is hard to recall. Doctors and therapists can use the idea that damaged ‘wiring’ (white matter) is especially important in women to tailor rehabilitation, for example using exercises that strengthen attention and processing speed. The findings suggest tracking not just visible lesions but also hidden damage in the brain’s wiring, which may affect decisions about tests or therapies. Overall, this helps people expect which thinking skills might need more daily support and where to focus brain-retraining exercises.
This study shows associations but cannot prove cause and effect, so we can’t say the brain changes definitely cause the thinking problems. The scans and tests were done at one time, so they don’t show how things change over years or how treatments might alter the pattern. Also, patients differed in disease type and treatments, which means results might not apply the same way to every person with MS.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds a brain‑seeking CD4 killer cell tied to MS and CMV exposure that may resist some treatme
Read More5/1/2026
Study shows after optic neuritis the ganglion cell layer (GCL) loses more tissue than the inner plex
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds specific spinal fluid proteins tied to early nerve damage in active MS, highlighting imm
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Molecular psychiatry often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.